Apellis Pharmaceuticals, Inc. has a twelve month low of $19.83 and a twelve month high of $94.75.

Source: https://www.etfdailynews.com/2023/09/03/apellis-pharmaceuticals-inc-nasdaqapls-is-finepoint-capital-lps-2nd-largest-position/

Hudson Bay Capital Management LP purchased a new stake in shares of Apellis Pharmaceuticals during the third quarter valued at approximately $476,000.

Source: https://www.etfdailynews.com/2023/12/19/apellis-pharmaceuticals-inc-nasdaqapls-receives-average-rating-of-moderate-buy-from-brokerages/

Jefferies Financial Group downgraded Apellis Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price target for the company from $70.00 to $40.00 in a report on Thursday, November 10th.

Source: https://www.americanbankingnews.com/2023/03/08/blackrock-inc-raises-holdings-in-apellis-pharmaceuticals-inc-nasdaqapls.html

Over 1 million people in the US and 5 million worldwide are affected by GA, providing a significant market opportunity for Apellis.

Source: https://seekingalpha.com/article/4589958-apellis-pharmaceuticals-is-poised-for-dominance-in-geographic-atrophy-market?source=feed_all_articles

Robert W. Baird lifted their price target on Apellis Pharmaceuticals from $105.00 to $115.00 in a report on Monday, July 17th.

Source: https://www.etfdailynews.com/2023/08/02/apellis-pharmaceuticals-nasdaqapls-downgraded-to-neutral-at-bank-of-america/

Vanguard Group Inc. raised its holdings in shares of Apellis Pharmaceuticals by 8.2% in the 1st quarter.

Source: https://www.etfdailynews.com/2023/02/16/169682-shares-in-apellis-pharmaceuticals-inc-nasdaqapls-purchased-by-california-public-employees-retirement-system/